Global Varicella Live Vaccine Market Research Report 2024
The varicella vaccine protects against chickenpox (varicella), a common and very contagious childhood viral illness. It also protects against shingles. It is a live attenuated vaccine, which means it contains a weakened form of the virus.
According to Mr Accuracy reports new survey, global Varicella Live Vaccine market is projected to reach US$ 5581.5 million in 2029, increasing from US$ 4174 million in 2022, with the CAGR of 4.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Varicella Live Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Varicella Live Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Astellas Pharma Inc.
CSL Limited
Emergent BioSolutions, Inc.
GlaxoSmithKline plc
Johnson & Johnson
MedImmune, LLC
Merck & Co., Inc.
Pfizer, Inc.
Sanofi Pasteur
Serum Institute of India Pvt. Ltd.
Bavarian Nordic
Mitsubishi Tanabe Pharma Corporation
Daiichi Sankyo
Biological E
Panacea Biotec
Segment by Type
Monovalent Vaccines
Multivalent Vaccines
Segment by Application
Chicken Pox Immunization
Herpes Zoster Immunization
Measles Immunization
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Varicella Live Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Table of Content
1 Varicella Live Vaccine Market Overview
1.1 Product Overview and Scope of Varicella Live Vaccine
1.2 Varicella Live Vaccine Segment by Type
1.2.1 Global Varicella Live Vaccine Market Value Comparison by Type (2024-2034)
1.2.2 Monovalent Vaccines
1.2.3 Multivalent Vaccines
1.3 Varicella Live Vaccine Segment by Application
1.3.1 Global Varicella Live Vaccine Market Value by Application: (2024-2034)
1.3.2 Chicken Pox Immunization
1.3.3 Herpes Zoster Immunization
1.3.4 Measles Immunization
1.3.5 Others
1.4 Global Varicella Live Vaccine Market Size Estimates and Forecasts
1.4.1 Global Varicella Live Vaccine Revenue 2018-2029
1.4.2 Global Varicella Live Vaccine Sales 2018-2029
1.4.3 Global Varicella Live Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Varicella Live Vaccine Market Competition by Manufacturers
2.1 Global Varicella Live Vaccine Sales Market Share by Manufacturers (2018-2024)
2.2 Global Varicella Live Vaccine Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Varicella Live Vaccine Average Price by Manufacturers (2018-2024)
2.4 Global Varicella Live Vaccine Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Varicella Live Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Varicella Live Vaccine, Product Type & Application
2.7 Varicella Live Vaccine Market Competitive Situation and Trends
2.7.1 Varicella Live Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Varicella Live Vaccine Players Market Share by Revenue
2.7.3 Global Varicella Live Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Varicella Live Vaccine Retrospective Market Scenario by Region
3.1 Global Varicella Live Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Varicella Live Vaccine Global Varicella Live Vaccine Sales by Region: 2018-2029
3.2.1 Global Varicella Live Vaccine Sales by Region: 2018-2024
3.2.2 Global Varicella Live Vaccine Sales by Region: 2024-2029
3.3 Global Varicella Live Vaccine Global Varicella Live Vaccine Revenue by Region: 2018-2029
3.3.1 Global Varicella Live Vaccine Revenue by Region: 2018-2024
3.3.2 Global Varicella Live Vaccine Revenue by Region: 2024-2029
3.4 North America Varicella Live Vaccine Market Facts & Figures by Country
3.4.1 North America Varicella Live Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Varicella Live Vaccine Sales by Country (2018-2029)
3.4.3 North America Varicella Live Vaccine Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Varicella Live Vaccine Market Facts & Figures by Country
3.5.1 Europe Varicella Live Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Varicella Live Vaccine Sales by Country (2018-2029)
3.5.3 Europe Varicella Live Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Varicella Live Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Varicella Live Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Varicella Live Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Varicella Live Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Varicella Live Vaccine Market Facts & Figures by Country
3.7.1 Latin America Varicella Live Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Varicella Live Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Varicella Live Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Varicella Live Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Varicella Live Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Varicella Live Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Varicella Live Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Varicella Live Vaccine Sales by Type (2018-2029)
4.1.1 Global Varicella Live Vaccine Sales by Type (2018-2024)
4.1.2 Global Varicella Live Vaccine Sales by Type (2024-2029)
4.1.3 Global Varicella Live Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Varicella Live Vaccine Revenue by Type (2018-2029)
4.2.1 Global Varicella Live Vaccine Revenue by Type (2018-2024)
4.2.2 Global Varicella Live Vaccine Revenue by Type (2024-2029)
4.2.3 Global Varicella Live Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Varicella Live Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Varicella Live Vaccine Sales by Application (2018-2029)
5.1.1 Global Varicella Live Vaccine Sales by Application (2018-2024)
5.1.2 Global Varicella Live Vaccine Sales by Application (2024-2029)
5.1.3 Global Varicella Live Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Varicella Live Vaccine Revenue by Application (2018-2029)
5.2.1 Global Varicella Live Vaccine Revenue by Application (2018-2024)
5.2.2 Global Varicella Live Vaccine Revenue by Application (2024-2029)
5.2.3 Global Varicella Live Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Varicella Live Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Astellas Pharma Inc.
6.1.1 Astellas Pharma Inc. Corporation Information
6.1.2 Astellas Pharma Inc. Description and Business Overview
6.1.3 Astellas Pharma Inc. Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Astellas Pharma Inc. Varicella Live Vaccine Product Portfolio
6.1.5 Astellas Pharma Inc. Recent Developments/Updates
6.2 CSL Limited
6.2.1 CSL Limited Corporation Information
6.2.2 CSL Limited Description and Business Overview
6.2.3 CSL Limited Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.2.4 CSL Limited Varicella Live Vaccine Product Portfolio
6.2.5 CSL Limited Recent Developments/Updates
6.3 Emergent BioSolutions, Inc.
6.3.1 Emergent BioSolutions, Inc. Corporation Information
6.3.2 Emergent BioSolutions, Inc. Description and Business Overview
6.3.3 Emergent BioSolutions, Inc. Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Emergent BioSolutions, Inc. Varicella Live Vaccine Product Portfolio
6.3.5 Emergent BioSolutions, Inc. Recent Developments/Updates
6.4 GlaxoSmithKline plc
6.4.1 GlaxoSmithKline plc Corporation Information
6.4.2 GlaxoSmithKline plc Description and Business Overview
6.4.3 GlaxoSmithKline plc Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.4.4 GlaxoSmithKline plc Varicella Live Vaccine Product Portfolio
6.4.5 GlaxoSmithKline plc Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Corporation Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Johnson & Johnson Varicella Live Vaccine Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 MedImmune, LLC
6.6.1 MedImmune, LLC Corporation Information
6.6.2 MedImmune, LLC Description and Business Overview
6.6.3 MedImmune, LLC Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.6.4 MedImmune, LLC Varicella Live Vaccine Product Portfolio
6.6.5 MedImmune, LLC Recent Developments/Updates
6.7 Merck & Co., Inc.
6.6.1 Merck & Co., Inc. Corporation Information
6.6.2 Merck & Co., Inc. Description and Business Overview
6.6.3 Merck & Co., Inc. Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Merck & Co., Inc. Varicella Live Vaccine Product Portfolio
6.7.5 Merck & Co., Inc. Recent Developments/Updates
6.8 Pfizer, Inc.
6.8.1 Pfizer, Inc. Corporation Information
6.8.2 Pfizer, Inc. Description and Business Overview
6.8.3 Pfizer, Inc. Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Pfizer, Inc. Varicella Live Vaccine Product Portfolio
6.8.5 Pfizer, Inc. Recent Developments/Updates
6.9 Sanofi Pasteur
6.9.1 Sanofi Pasteur Corporation Information
6.9.2 Sanofi Pasteur Description and Business Overview
6.9.3 Sanofi Pasteur Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Sanofi Pasteur Varicella Live Vaccine Product Portfolio
6.9.5 Sanofi Pasteur Recent Developments/Updates
6.10 Serum Institute of India Pvt. Ltd.
6.10.1 Serum Institute of India Pvt. Ltd. Corporation Information
6.10.2 Serum Institute of India Pvt. Ltd. Description and Business Overview
6.10.3 Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Product Portfolio
6.10.5 Serum Institute of India Pvt. Ltd. Recent Developments/Updates
6.11 Bavarian Nordic
6.11.1 Bavarian Nordic Corporation Information
6.11.2 Bavarian Nordic Varicella Live Vaccine Description and Business Overview
6.11.3 Bavarian Nordic Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Bavarian Nordic Varicella Live Vaccine Product Portfolio
6.11.5 Bavarian Nordic Recent Developments/Updates
6.12 Mitsubishi Tanabe Pharma Corporation
6.12.1 Mitsubishi Tanabe Pharma Corporation Corporation Information
6.12.2 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Description and Business Overview
6.12.3 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Product Portfolio
6.12.5 Mitsubishi Tanabe Pharma Corporation Recent Developments/Updates
6.13 Daiichi Sankyo
6.13.1 Daiichi Sankyo Corporation Information
6.13.2 Daiichi Sankyo Varicella Live Vaccine Description and Business Overview
6.13.3 Daiichi Sankyo Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Daiichi Sankyo Varicella Live Vaccine Product Portfolio
6.13.5 Daiichi Sankyo Recent Developments/Updates
6.14 Biological E
6.14.1 Biological E Corporation Information
6.14.2 Biological E Varicella Live Vaccine Description and Business Overview
6.14.3 Biological E Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Biological E Varicella Live Vaccine Product Portfolio
6.14.5 Biological E Recent Developments/Updates
6.15 Panacea Biotec
6.15.1 Panacea Biotec Corporation Information
6.15.2 Panacea Biotec Varicella Live Vaccine Description and Business Overview
6.15.3 Panacea Biotec Varicella Live Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Panacea Biotec Varicella Live Vaccine Product Portfolio
6.15.5 Panacea Biotec Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Varicella Live Vaccine Industry Chain Analysis
7.2 Varicella Live Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Varicella Live Vaccine Production Mode & Process
7.4 Varicella Live Vaccine Sales and Marketing
7.4.1 Varicella Live Vaccine Sales Channels
7.4.2 Varicella Live Vaccine Distributors
7.5 Varicella Live Vaccine Customers
8 Varicella Live Vaccine Market Dynamics
8.1 Varicella Live Vaccine Industry Trends
8.2 Varicella Live Vaccine Market Drivers
8.3 Varicella Live Vaccine Market Challenges
8.4 Varicella Live Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Figure
List of Tables
Table 1. Global Varicella Live Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Varicella Live Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Varicella Live Vaccine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Varicella Live Vaccine Sales (K Doses) of Key Manufacturers (2018-2024)
Table 5. Global Varicella Live Vaccine Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Varicella Live Vaccine Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Varicella Live Vaccine Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Varicella Live Vaccine Average Price (USD/Dose) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Varicella Live Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Varicella Live Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Varicella Live Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Varicella Live Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Varicella Live Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Live Vaccine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Varicella Live Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Varicella Live Vaccine Sales by Region (2018-2024) & (K Doses)
Table 18. Global Varicella Live Vaccine Sales Market Share by Region (2018-2024)
Table 19. Global Varicella Live Vaccine Sales by Region (2024-2029) & (K Doses)
Table 20. Global Varicella Live Vaccine Sales Market Share by Region (2024-2029)
Table 21. Global Varicella Live Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Varicella Live Vaccine Revenue Market Share by Region (2018-2024)
Table 23. Global Varicella Live Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Varicella Live Vaccine Revenue Market Share by Region (2024-2029)
Table 25. North America Varicella Live Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Varicella Live Vaccine Sales by Country (2018-2024) & (K Doses)
Table 27. North America Varicella Live Vaccine Sales by Country (2024-2029) & (K Doses)
Table 28. North America Varicella Live Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Varicella Live Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Varicella Live Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Varicella Live Vaccine Sales by Country (2018-2024) & (K Doses)
Table 32. Europe Varicella Live Vaccine Sales by Country (2024-2029) & (K Doses)
Table 33. Europe Varicella Live Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Varicella Live Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Varicella Live Vaccine Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Varicella Live Vaccine Sales by Region (2018-2024) & (K Doses)
Table 37. Asia Pacific Varicella Live Vaccine Sales by Region (2024-2029) & (K Doses)
Table 38. Asia Pacific Varicella Live Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Varicella Live Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Varicella Live Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Varicella Live Vaccine Sales by Country (2018-2024) & (K Doses)
Table 42. Latin America Varicella Live Vaccine Sales by Country (2024-2029) & (K Doses)
Table 43. Latin America Varicella Live Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Varicella Live Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Varicella Live Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Varicella Live Vaccine Sales by Country (2018-2024) & (K Doses)
Table 47. Middle East & Africa Varicella Live Vaccine Sales by Country (2024-2029) & (K Doses)
Table 48. Middle East & Africa Varicella Live Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Varicella Live Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Varicella Live Vaccine Sales (K Doses) by Type (2018-2024)
Table 51. Global Varicella Live Vaccine Sales (K Doses) by Type (2024-2029)
Table 52. Global Varicella Live Vaccine Sales Market Share by Type (2018-2024)
Table 53. Global Varicella Live Vaccine Sales Market Share by Type (2024-2029)
Table 54. Global Varicella Live Vaccine Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Varicella Live Vaccine Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Varicella Live Vaccine Revenue Market Share by Type (2018-2024)
Table 57. Global Varicella Live Vaccine Revenue Market Share by Type (2024-2029)
Table 58. Global Varicella Live Vaccine Price (USD/Dose) by Type (2018-2024)
Table 59. Global Varicella Live Vaccine Price (USD/Dose) by Type (2024-2029)
Table 60. Global Varicella Live Vaccine Sales (K Doses) by Application (2018-2024)
Table 61. Global Varicella Live Vaccine Sales (K Doses) by Application (2024-2029)
Table 62. Global Varicella Live Vaccine Sales Market Share by Application (2018-2024)
Table 63. Global Varicella Live Vaccine Sales Market Share by Application (2024-2029)
Table 64. Global Varicella Live Vaccine Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Varicella Live Vaccine Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Varicella Live Vaccine Revenue Market Share by Application (2018-2024)
Table 67. Global Varicella Live Vaccine Revenue Market Share by Application (2024-2029)
Table 68. Global Varicella Live Vaccine Price (USD/Dose) by Application (2018-2024)
Table 69. Global Varicella Live Vaccine Price (USD/Dose) by Application (2024-2029)
Table 70. Astellas Pharma Inc. Corporation Information
Table 71. Astellas Pharma Inc. Description and Business Overview
Table 72. Astellas Pharma Inc. Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 73. Astellas Pharma Inc. Varicella Live Vaccine Product
Table 74. Astellas Pharma Inc. Recent Developments/Updates
Table 75. CSL Limited Corporation Information
Table 76. CSL Limited Description and Business Overview
Table 77. CSL Limited Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 78. CSL Limited Varicella Live Vaccine Product
Table 79. CSL Limited Recent Developments/Updates
Table 80. Emergent BioSolutions, Inc. Corporation Information
Table 81. Emergent BioSolutions, Inc. Description and Business Overview
Table 82. Emergent BioSolutions, Inc. Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 83. Emergent BioSolutions, Inc. Varicella Live Vaccine Product
Table 84. Emergent BioSolutions, Inc. Recent Developments/Updates
Table 85. GlaxoSmithKline plc Corporation Information
Table 86. GlaxoSmithKline plc Description and Business Overview
Table 87. GlaxoSmithKline plc Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 88. GlaxoSmithKline plc Varicella Live Vaccine Product
Table 89. GlaxoSmithKline plc Recent Developments/Updates
Table 90. Johnson & Johnson Corporation Information
Table 91. Johnson & Johnson Description and Business Overview
Table 92. Johnson & Johnson Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 93. Johnson & Johnson Varicella Live Vaccine Product
Table 94. Johnson & Johnson Recent Developments/Updates
Table 95. MedImmune, LLC Corporation Information
Table 96. MedImmune, LLC Description and Business Overview
Table 97. MedImmune, LLC Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 98. MedImmune, LLC Varicella Live Vaccine Product
Table 99. MedImmune, LLC Recent Developments/Updates
Table 100. Merck & Co., Inc. Corporation Information
Table 101. Merck & Co., Inc. Description and Business Overview
Table 102. Merck & Co., Inc. Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 103. Merck & Co., Inc. Varicella Live Vaccine Product
Table 104. Merck & Co., Inc. Recent Developments/Updates
Table 105. Pfizer, Inc. Corporation Information
Table 106. Pfizer, Inc. Description and Business Overview
Table 107. Pfizer, Inc. Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 108. Pfizer, Inc. Varicella Live Vaccine Product
Table 109. Pfizer, Inc. Recent Developments/Updates
Table 110. Sanofi Pasteur Corporation Information
Table 111. Sanofi Pasteur Description and Business Overview
Table 112. Sanofi Pasteur Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 113. Sanofi Pasteur Varicella Live Vaccine Product
Table 114. Sanofi Pasteur Recent Developments/Updates
Table 115. Serum Institute of India Pvt. Ltd. Corporation Information
Table 116. Serum Institute of India Pvt. Ltd. Description and Business Overview
Table 117. Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 118. Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Product
Table 119. Serum Institute of India Pvt. Ltd. Recent Developments/Updates
Table 120. Bavarian Nordic Corporation Information
Table 121. Bavarian Nordic Description and Business Overview
Table 122. Bavarian Nordic Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 123. Bavarian Nordic Varicella Live Vaccine Product
Table 124. Bavarian Nordic Recent Developments/Updates
Table 125. Mitsubishi Tanabe Pharma Corporation Corporation Information
Table 126. Mitsubishi Tanabe Pharma Corporation Description and Business Overview
Table 127. Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 128. Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Product
Table 129. Mitsubishi Tanabe Pharma Corporation Recent Developments/Updates
Table 130. Daiichi Sankyo Corporation Information
Table 131. Daiichi Sankyo Description and Business Overview
Table 132. Daiichi Sankyo Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 133. Daiichi Sankyo Varicella Live Vaccine Product
Table 134. Daiichi Sankyo Recent Developments/Updates
Table 135. Biological E Corporation Information
Table 136. Biological E Description and Business Overview
Table 137. Biological E Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 138. Biological E Varicella Live Vaccine Product
Table 139. Biological E Recent Developments/Updates
Table 140. Panacea Biotec Corporation Information
Table 141. Panacea Biotec Description and Business Overview
Table 142. Panacea Biotec Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 143. Panacea Biotec Varicella Live Vaccine Product
Table 144. Panacea Biotec Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Varicella Live Vaccine Distributors List
Table 148. Varicella Live Vaccine Customers List
Table 149. Varicella Live Vaccine Market Trends
Table 150. Varicella Live Vaccine Market Drivers
Table 151. Varicella Live Vaccine Market Challenges
Table 152. Varicella Live Vaccine Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Varicella Live Vaccine
Figure 2. Global Varicella Live Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Varicella Live Vaccine Market Share by Type in 2022 & 2029
Figure 4. Monovalent Vaccines Product Picture
Figure 5. Multivalent Vaccines Product Picture
Figure 6. Global Varicella Live Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Varicella Live Vaccine Market Share by Application in 2022 & 2029
Figure 8. Chicken Pox Immunization
Figure 9. Herpes Zoster Immunization
Figure 10. Measles Immunization
Figure 11. Others
Figure 12. Global Varicella Live Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Varicella Live Vaccine Market Size (2018-2029) & (US$ Million)
Figure 14. Global Varicella Live Vaccine Sales (2018-2029) & (K Doses)
Figure 15. Global Varicella Live Vaccine Average Price (USD/Dose) & (2018-2029)
Figure 16. Varicella Live Vaccine Report Years Considered
Figure 17. Varicella Live Vaccine Sales Share by Manufacturers in 2022
Figure 18. Global Varicella Live Vaccine Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Varicella Live Vaccine Players: Market Share by Revenue in 2022
Figure 20. Varicella Live Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Varicella Live Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Varicella Live Vaccine Sales Market Share by Country (2018-2029)
Figure 23. North America Varicella Live Vaccine Revenue Market Share by Country (2018-2029)
Figure 24. U.S. Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Varicella Live Vaccine Sales Market Share by Country (2018-2029)
Figure 27. Europe Varicella Live Vaccine Revenue Market Share by Country (2018-2029)
Figure 28. Germany Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Varicella Live Vaccine Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Varicella Live Vaccine Revenue Market Share by Region (2018-2029)
Figure 35. China Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Taiwan Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Philippines Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Latin America Varicella Live Vaccine Sales Market Share by Country (2018-2029)
Figure 46. Latin America Varicella Live Vaccine Revenue Market Share by Country (2018-2029)
Figure 47. Mexico Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Brazil Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Argentina Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Varicella Live Vaccine Sales Market Share by Country (2018-2029)
Figure 51. Middle East & Africa Varicella Live Vaccine Revenue Market Share by Country (2018-2029)
Figure 52. Turkey Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. U.A.E Varicella Live Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Global Sales Market Share of Varicella Live Vaccine by Type (2018-2029)
Figure 56. Global Revenue Market Share of Varicella Live Vaccine by Type (2018-2029)
Figure 57. Global Varicella Live Vaccine Price (USD/Dose) by Type (2018-2029)
Figure 58. Global Sales Market Share of Varicella Live Vaccine by Application (2018-2029)
Figure 59. Global Revenue Market Share of Varicella Live Vaccine by Application (2018-2029)
Figure 60. Global Varicella Live Vaccine Price (USD/Dose) by Application (2018-2029)
Figure 61. Varicella Live Vaccine Value Chain
Figure 62. Varicella Live Vaccine Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices